Inflammatory conditions medicine developer Mesoblast (ASX:MSB) is trading up more than 3% after striking a funding deal with its largest shareholder Gregory George for AUD$72.7 million in convertible notes. The funds will be available for the company to unleash its marketing strategy, once it has US Food and Drug Administration approval for Mesoblast’s lead cellular drug candidate Ryoncil for the treatment of children with steroid refractory acute graft versus host disease, which can be a complication of stem cell transplants. Mesoblast expects that FDA decision will land by early next year. I…